SciSparc's NeuroThera Labs Initiates Phase IIb Clinical Trial Of SCI-110 For Tourette Syndrome
SciSparc Ltd. (SPRC) said its subsidiary NeuroThera Labs (NTLX.V) started a Phase IIb site for SCI-110, an investigational oral treatment for adult Tourette syndrome. The randomized, double-blind, placebo-controlled cross-over trial will assess tic severity via the Yale Global Tic Severity Scale at weeks 12 and 26. Company cites Phase IIa average tic reduction of 21%.
How this was made
The 30-second read
Why it matters
The initiation of Phase IIb trial sites at Hannover Medical School (with additional planned sites at Yale Child Study Center and Tel Aviv Sourasky Medical Center) advances the program toward efficacy and safety/tolerability evaluation using the Yale Global Tic Severity Scale at weeks 12 and 26.
Market read
This is a concrete clinical development milestone (Phase IIb trial-site initiation) with defined endpoints, which can influence expectations for future data timing.
What to watch
Key near-term drivers are enrollment speed, patient retention in a cross-over design, and whether Phase IIa results translate into Phase IIb endpoints at weeks 12 and 26.
Background
SCI-110 is a combination of dronabinol and palmitoylethanolamide in a single dosage form being developed for adult Tourette syndrome; Phase IIb is designed to assess tic severity changes.
Ticker impact
SciSparc announced its subsidiary initiated a Phase IIb trial site for SCI-110 in adult Tourette syndrome, advancing its clinical pipeline.
Near-term reaction likely modest, with upside skew only if investors interpret the start as de-risking timelines.
The article discloses commencement of Phase IIb trial sites and design details, but provides no new clinical results beyond prior Phase IIa claims.
Market effects
Adds incremental momentum to the CNS/biotech development narrative around cannabinoid-based therapies for Tourette syndrome.
Trial activity in Germany and additional sites in the US and Israel may support cross-region clinical execution expectations.
Tourette syndrome treatment development remains a niche CNS area, so global read-through is likely limited.
Counterpoint
Trial-site initiation can be largely procedural; without enrollment pace or interim data, the market may discount the news quickly.
Key entities
- companySciSparc Ltd.
Parent company announcing Phase IIb trial-site initiation for SCI-110 via its subsidiary.
- companyNeuroThera Labs Inc.
Subsidiary initiating Phase IIb clinical trial site for SCI-110 in Tourette syndrome.
- investigational drugSCI-110
Dronabinol plus palmitoylethanolamide candidate for reducing tics in adults with Tourette syndrome.
- trial siteHannover Medical School
Germany site where the Phase IIb trial commenced.
